Table 2.
Correlation of HHLA2 expression with clinicopathological parameters in ovarian cancer
| Variable | Number of patients | HHLA2 Expression | ||
|---|---|---|---|---|
| + | − | P Value | ||
| Age | ||||
| ≥ 50 | 42 | 7 | 35 | 1.000 |
| < 50 | 22 | 4 | 18 | |
| Histological type | ||||
| Serous adenocarcinoma | 50 | 8 | 42 | 0.940 |
| Others | 14 | 3 | 11 | |
| Differentiation | ||||
| Poor | 26 | 2 | 24 | 0.027 |
| Moderate | 25 | 4 | 21 | |
| Well | 13 | 5 | 8 | |
| FIGO Stage | ||||
| I | 9 | 3 | 6 | 0.160 |
| II | 6 | 1 | 5 | |
| III | 36 | 6 | 30 | |
| IV | 13 | 1 | 12 | |
| Metastasis | ||||
| + | 51 | 8 | 43 | 0.532 |
| − | 13 | 3 | 10 | |
| Ascites | ||||
| + | 11 | 1 | 10 | 0.732 |
| − | 53 | 10 | 43 | |
| Vessel Invasion | ||||
| + | 3 | 0 | 3 | 1.000 |
| − | 61 | 11 | 50 | |
| Lymph Node | ||||
| + | 8 | 2 | 6 | 0.900 |
| − | 56 | 9 | 47 | |
| Platinum Sensitivity | ||||
| Platinum sensitive | 50 | 8 | 42 | 0.940 |
| Platinum resistance | 14 | 3 | 11 | |
| Relapse | ||||
| + | 27 | 4 | 23 | 0.925 |
| − | 37 | 7 | 30 | |
| Serum CA125 Before Surgery | ||||
| < 35 | 4 | 1 | 3 | 0.539 |
| ≥ 35 | 60 | 10 | 50 | |
| CA125 | ||||
| + | 37 | 5 | 32 | 0.148 |
| − | 5 | 2 | 5 | |
| Unknown | 19 | 4 | 16 | |
| ER | ||||
| + | 39 | 8 | 34 | 1.000 |
| − | 17 | 3 | 15 | |
| Unknown | 4 | 0 | 4 | |
| PR | ||||
| + | 33 | 6 | 29 | 1.000 |
| − | 23 | 5 | 20 | |
| Unknown | 4 | 0 | 4 | |
Bold value indicates P < 0.05
ER, Estrogen Receptor, PR Progesterone Receptor